FDA recommends Omicron strains in new boosters, that to the Future Framework scheme

On June 30, 2022 the FDA recommended [2] to vaccine manufactures to include Omicron BA.4/5 component, together with the extinct original strain, in their September booster doses as the effectiveness of the current (still Wuhan/original strain) vaccines wane so fast.

The FDA have adopted the “future framework” scheme (introduced April 6, 2022)  which was voted on at June 28, 2022 VRBPAC meeting, which will allow reformulated mRNA COVID-19 shots to gain approval WITHOUT further clinical trials.  [1]

A week earlier NIH researches had found better antibody responses from natural infections vs vaccination with Moderna, of which at best offer only short-lived protection.

A June 28, 2022 Pfizer presentation to the FDA’s VRBPAC meeting shows they were already developing a bivalent vaccine! [3]